ZOMETA in Advanced Cancers

For non-US healthcare professionals: Get information about ZOMETA and its product characteristics.

Protection Across Advanced
Malignancies

This is an international site for Zometa^® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Zometa Information for US residents Zometa Information for Patients Outside the US

Welcome to the ZOMETA Product Website

ZOMETA is approved for use in
95 countries
around the world.

ZOMETA Country-Level Websites

Below is a list of the countries that host a ZOMETA website based on local label and in local language. They are intended for Healthcare Professional (HCPs) only. Click on any of the links to be redirected to that country-level website.

ZOMETA International Website

This website is intended for Healthcare Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus .

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)

Text size:

ZOMETA is the most prescribed treatment for the prevention of skeletal-related events (SREs)¹

ZOMETA is the most widely used bone-targeted agent¹

More than 4 million patients treated worldwide¹
Approvals in 95 countries¹
More than 140 completed or active studies in the oncology setting²

ZOMETA is indicated across a broader range of malignancy types than any other bone-targeted agent^3-8

References: 1. Data on file. Novartis Pharma AG. 2. www.clinicaltrials.gov. Accessed November 6, 2009. 3. ZOMETA Summary of Product Characteristics. Novartis Pharma AG. 4. Bondronat (tablets) Summary of Product Characteristics. Roche Pharmaceuticals. 5. Bondronat (IV) Summary of Product Characteristics. Roche Pharmaceuticals. 6. Bonefos (tablets) Summary of Product Characteristics. Bayer Schering Pharma. 7. Bonefos (IV) Product Monograph. Berlex Canada Inc. 8. Aredia Summary of Product Characteristics. Novartis Pharma AG.

Protection Across Advanced Malignancies

Welcome to the ZOMETA Product Website

ZOMETA is approved for use in 95 countries around the world.